7-[2-(シクロプロピルメトキシ)-6-ヒドロキシフェニル]-1,4-ジヒドロ-5-[(3S)-3-ピペリジニル]-2H-ピリド[2,3-d][1,3]オキサジン-2-オン・塩酸塩

7-[2-(シクロプロピルメトキシ)-6-ヒドロキシフェニル]-1,4-ジヒドロ-5-[(3S)-3-ピペリジニル]-2H-ピリド[2,3-d][1,3]オキサジン-2-オン・塩酸塩 価格

7-[2-(シクロプロピルメトキシ)-6-ヒドロキシフェニル]-1,4-ジヒドロ-5-[(3S)-3-ピペリジニル]-2H-ピリド[2,3-d][1,3]オキサジン-2-オン・塩酸塩 化学特性,用途語,生産方法

• Biochem/physiol Actions

  KINK-1 (Kinase Inhibitor of NF-ΚB-1; Bay 65-1942; CmpdA; Compound A) is an ATP-competitive, IKKβ-selective IΚB kinase (IKK) inhibitor (Ki against ATP = 2 nM/IKKβ and 135 nM/IKKα) that potently inhibits IKKβ-catalyzed GST-IΚBα(1–54) phosphorylation (IC50 = 4 nM, 200 nM ATP) without affecting (IC50 >10μM) IKK3 or 27 other kinases, lipases, phosphatases, caspases, and MMPs. KINK-1 effectively inhibits NF-ΚB activation and cytokines production in various human and murine cultures (IC50 from 18 to 502 nM) and is efficacious against LPS-induced plasma TNF-α production in mice and rats in vivo (EC50 = 9.1 and 6.6 mg/kg p.o., repectively) with good pharmacokinetic profile and oral availability. KINK-1 is also shown to effectively inhibit OVA-induced lung inflammation in a rat model of asthma (ED50 <0.3 mg/kg p.o.) without adverse effects to the animals.

7-[2-(シクロプロピルメトキシ)-6-ヒドロキシフェニル]-1,4-ジヒドロ-5-[(3S)-3-ピペリジニル]-2H-ピリド[2,3-d][1,3]オキサジン-2-オン・塩酸塩 生産企業

Global(37)Suppliers

600734-06-3, 7-[2-(シクロプロピルメトキシ)-6-ヒドロキシフェニル]-1,4-ジヒドロ-5-[(3S)-3-ピペリジニル]-2H-ピリド[2,3-d][1,3]オキサジン-2-オン・塩酸塩 キーワード